



(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 25/28* (2006.01)
A61K 31/4985 (2006.01)

(21) International Application Number:
PCT/IB2015/051988

(22) International Filing Date:
18 March 2015 (18.03.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/973,436 1 April 2014 (01.04.2014) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: **AM ENDE, Christopher William**; 32 Hunting
Ridge Drive, Mystic, Connecticut 06355 (US).
HUMPHREY, John Michael; 110 Haley Road, Mystic,
Connecticut 06355 (US). **JOHNSON, Douglas Scott**; 85
Adin Drive, Concord, Massachusetts 01742 (US).
KAUFFMAN, Gregory Wayne; 30 Boulder Way, East
Greenwich, Rhode Island 02818 (US). **PETTERSSON,
Martin Youngjin**; 3 Gilson Road, Littleton, Massachusetts
01460 (US). **RANKIC, Danica Antonia**; 304 Main Street,
Apt. 1A, Niantic, Connecticut 06357 (US). **STEPAN, Ant-
onia Friederike**; 1110 Beacon Street, Apt. 2B, Brookline,
Massachusetts 02446 (US). **VERHOEST, Patrick
Robert**; 23 Calvin Road, Newton, Massachusetts 02460
(US).

(74) Agent: **OLSON, A. Dean**; Pfizer Worldwide Research &
Development, Eastern Point Road MS8260-2141, Groton,
Connecticut 06340 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

[Continued on next page]

(54) Title: CHROMENE AND 1,1 A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS
GAMMA-SECRETASE MODULATORS



Formula I

(57) Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I), wherein X, R¹, R^{2a}, R^{2b}, R^{4a}, R^{4b}, R^{5a}, R^{5b}, R⁶, R⁷, y and z are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. These compounds are γ -secretase modulators, useful for the treatment of neurodegenerative and/ or neurological disorders such as Alzheimer's disease and Down's syndrome.



Published:

— *with international search report (Art. 21(3))*